PDF(Pubmed)
Abstract：
UNASSIGNED: Biosimilars can improve patient access to biological medicines. Although biosimilars have been shown to be equally effective and safe, some patients remain reluctant to transition to biosimilars. Pharmacists may support patients changing to biosimilars and are often at the frontline for dealing with queries and concerns, but their confidence and readiness for this role are unclear.
UNASSIGNED: This study examines pharmacists\' confidence in explaining biosimilars to patients and explores the information they would provide in response to common queries.
UNASSIGNED: Practicing community, hospital, and primary care pharmacists (N = 142) in New Zealand completed an Internet-based survey on their experience and familiarity with bio-originators and biosimilars, attitudes and concerns towards biosimilars, confidence in explaining key concepts, and responses to common queries. A hierarchical linear regression was conducted to examine possible factors associated with confidence in explaining biosimilars, and a content synthesis was conducted to examine responses to common patient queries.
UNASSIGNED: Pharmacists were most confident in explaining how biosimilars are administered, their efficacy, and cost-saving, and least confident in describing manufacturing and testing. Respondents who had more positive attitudes (B = 1.64, p < .001) and more familiarity with biosimilars (B = 27.15, p < .001) were more confident in educating patients. Pharmacists\' main concerns about biosimilars included reduced efficacy, safety, and a lack of knowledge and acceptance. Responses to common queries were diverse but further highlighted several gaps in knowledge. Gaps included being unable to define biosimilars, provide information on side effects, and believing that biosimilars undergo the same testing process as bio-originators. Pharmacists wanted resources (written and Internet-based) to improve their knowledge and ability to educate patients.
UNASSIGNED: Pharmacists reported a lack of knowledge and confidence in explaining manufacturing processes and testing of biosimilars. Additional resources are needed to support their practice and may help improve patient and companion acceptance of biosimilars.
UNASSIGNED: This study examines pharmacists\' confidence in explaining biosimilars to patients and explores the information they would provide in response to common queries.
UNASSIGNED: Practicing community, hospital, and primary care pharmacists (N = 142) in New Zealand completed an Internet-based survey on their experience and familiarity with bio-originators and biosimilars, attitudes and concerns towards biosimilars, confidence in explaining key concepts, and responses to common queries. A hierarchical linear regression was conducted to examine possible factors associated with confidence in explaining biosimilars, and a content synthesis was conducted to examine responses to common patient queries.
UNASSIGNED: Pharmacists were most confident in explaining how biosimilars are administered, their efficacy, and cost-saving, and least confident in describing manufacturing and testing. Respondents who had more positive attitudes (B = 1.64, p < .001) and more familiarity with biosimilars (B = 27.15, p < .001) were more confident in educating patients. Pharmacists\' main concerns about biosimilars included reduced efficacy, safety, and a lack of knowledge and acceptance. Responses to common queries were diverse but further highlighted several gaps in knowledge. Gaps included being unable to define biosimilars, provide information on side effects, and believing that biosimilars undergo the same testing process as bio-originators. Pharmacists wanted resources (written and Internet-based) to improve their knowledge and ability to educate patients.
UNASSIGNED: Pharmacists reported a lack of knowledge and confidence in explaining manufacturing processes and testing of biosimilars. Additional resources are needed to support their practice and may help improve patient and companion acceptance of biosimilars.
摘要：
未经评估：生物仿制药可以改善患者获得生物药物的机会。尽管生物仿制药已被证明同样有效和安全，一些患者仍然不愿意过渡到生物仿制药。药剂师可能会支持患者改用生物仿制药，并且经常在前线处理疑问和问题，但是他们对这个角色的信心和准备尚不清楚。
UNASSIGNED：这项研究考察了药剂师对向患者解释生物仿制药的信心，并探讨了他们在回答常见问题时提供的信息。
未经授权：实践社区，医院,新西兰的初级保健药剂师（N=142）完成了一项基于互联网的调查，调查了他们对生物起源和生物仿制药的经验和熟悉程度，对生物仿制药的态度和关注，有信心解释关键概念，和对常见查询的响应。进行了分层线性回归，以检查与解释生物仿制药的信心相关的可能因素，并进行了内容合成以检查对常见患者查询的响应。
未经授权：药剂师对如何使用生物仿制药非常有信心，其功效,节约成本,在描述制造和测试时最没有信心。有更积极的态度（B=1.64，p<.001）和更熟悉生物仿制药（B=27.15，p<.001）的受访者对教育患者更有信心。药剂师对生物仿制药的主要担忧包括疗效降低，安全,缺乏知识和接受。对常见查询的响应多种多样，但进一步强调了知识上的一些差距。差距包括无法定义生物仿制药，提供有关副作用的信息，并认为生物仿制药与生物鼻祖经历相同的测试过程。药剂师需要资源（书面和基于互联网的）来提高他们的知识和教育患者的能力。
UNASSIGNED：药剂师报告说，在解释生物仿制药的制造工艺和测试方面缺乏知识和信心。需要额外的资源来支持他们的实践，并可能有助于提高患者和同伴对生物仿制药的接受度。
UNASSIGNED：这项研究考察了药剂师对向患者解释生物仿制药的信心，并探讨了他们在回答常见问题时提供的信息。
未经授权：实践社区，医院,新西兰的初级保健药剂师（N=142）完成了一项基于互联网的调查，调查了他们对生物起源和生物仿制药的经验和熟悉程度，对生物仿制药的态度和关注，有信心解释关键概念，和对常见查询的响应。进行了分层线性回归，以检查与解释生物仿制药的信心相关的可能因素，并进行了内容合成以检查对常见患者查询的响应。
未经授权：药剂师对如何使用生物仿制药非常有信心，其功效,节约成本,在描述制造和测试时最没有信心。有更积极的态度（B=1.64，p<.001）和更熟悉生物仿制药（B=27.15，p<.001）的受访者对教育患者更有信心。药剂师对生物仿制药的主要担忧包括疗效降低，安全,缺乏知识和接受。对常见查询的响应多种多样，但进一步强调了知识上的一些差距。差距包括无法定义生物仿制药，提供有关副作用的信息，并认为生物仿制药与生物鼻祖经历相同的测试过程。药剂师需要资源（书面和基于互联网的）来提高他们的知识和教育患者的能力。
UNASSIGNED：药剂师报告说，在解释生物仿制药的制造工艺和测试方面缺乏知识和信心。需要额外的资源来支持他们的实践，并可能有助于提高患者和同伴对生物仿制药的接受度。
